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Creatine transporter deficiency is a metabolic disorder characterized by intellectual disability, autistic-like behaviour and epilepsy.
There is currently no cure for creatine transporter deficiency, and reliable biomarkers of translational value for monitoring disease
progression and response to therapeutics are sorely lacking. Here, we found that mice lacking functional creatine transporter dis-
play a significant alteration of neural oscillations in the EEG and a severe epileptic phenotype that are recapitulated in patients
with creatine transporter deficiency. In-depth examination of knockout mice for creatine transporter also revealed that a decrease
in EEG theta power is predictive of the manifestation of spontaneous seizures, a frequency that is similarly affected in patients com-
pared to healthy controls. In addition, knockout mice have a highly specific increase in haemodynamic responses in the cerebral
cortex following sensory stimuli. Principal component and Random Forest analyses highlighted that these functional variables ex-
hibit a high performance in discriminating between pathological and healthy phenotype. Overall, our findings identify novel, trans-
lational and non-invasive biomarkers for the analysis of brain function in creatine transporter deficiency, providing a very reliable
protocol to longitudinally monitor the efficacy of potential therapeutic strategies in preclinical, and possibly clinical, studies.
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Introduction
A disruption of brain energy metabolism has been asso-
ciated with multiple psychiatric and neurological disor-
ders, including for instance schizophrenia, Rett
syndrome and a subset of autism spectrum disorders
(e.g. Müller and Can, 2014; Rose et al., 2018; Dwir
et al., 2019). Creatine (Cr) transporter deficiency is a re-
cessive X-linked inherited alteration of metabolism
(OMIM #300352), characterized by greatly diminished
or undetectable levels of Cr in the brain, and presenting
with early intellectual disability, symptoms overlapping
with autism spectrum disorders, seizures and motor
abnormalities (Cecil et al., 2001; van de Kamp et al.,
2014). Creatine transporter deficiency is caused by
mutations in Slc6a8 gene and loss of function of Cr
transporter 1 (CrT), which transports Cr both across
the blood–brain barrier and into the cells (Nash et al.,
1994). The prevalence of creatine transporter deficiency
is unknown, but the disorder has been estimated to ac-
count for 1–2% of males with non-syndromic mental
disability (van de Kamp et al., 2014). Although rare,
creatine transporter deficiency represents a major issue
in health care, as it is a chronic illness requiring life-
long care and resulting in a large impact on the quality
of life of both patients and caregivers, as well as a bur-
den on the healthcare system. There are no therapies for
this disorder and the current standard of care is a pal-
liative approach for managing seizures and behavioural
problems (van de Kamp et al., 2014). Previous attempts
to rescue Cr content in the brain of creatine transporter
deficiency patients by exploiting nutritional supplements
or Cr analogues have met with very limited success
(Chilosi et al., 2008; Mercimek-Mahmutoglu et al.,
2010; Kurosawa et al., 2012; Valayannopoulos et al.,
2012; Dunbar et al., 2014; Jaggumantri et al., 2015).
Recently, CrT knockout murine models that recapitulate
many aspects of the human disease have become avail-
able, supporting the preclinical development of therapeu-
tics and a better understanding of creatine transporter
deficiency pathophysiology (Skelton et al., 2011;
Kurosawa et al., 2012; Baroncelli et al., 2016: Udobi
et al., 2018; Molinaro et al., 2019). However, the effi-
cacy study of novel potential treatments is hindered by
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the scarcity of unbiased, quantitative biomarkers for
monitoring brain development and function.
EEG and sensory-evoked responses are readily applic-
able to humans and widely used for non-invasive assess-
ment of cortical function, making electrophysiological
measurements or functional imaging ecologically ideal
translational tools for functional analyses in children
with neurodevelopmental disorders (Nelson and
McCleery, 2008; Lloyd-Fox et al., 2010; Vanderwert
and Nelson, 2014). Accordingly, previous studies
reported that a standardized inspection of EEG and cor-
tical responses to sensory stimuli is suitable to reveal, in
both animal models and patients, stage-specific altera-
tions in other disorders affecting neurodevelopment
(Bosl et al., 2011; Durand et al., 2012; LeBlanc et al.,
2015; Boggio et al., 2016; Mazziotti et al., 2017;
Bowman and Varcin, 2018; Lupori et al., 2019).
Abnormal EEG waveforms have been previously docu-
mented in creatine transporter deficiency patients, indi-
cating diffuse slowing, interictal theta activity, specific
sharp abnormalities and focal/generalized paroxysmal or
slow abnormalities (Schiaffino et al., 2005; Póo-
Argüelles et al., 2006; Mancardi et al., 2007; Fons
et al., 2009; Leuzzi et al., 2013). However, a quantita-
tive examination of creatine transporter deficiency elec-
troclinical features is still missing.
Here, we performed an extensive functional analysis in
knockout mice lacking CrT (CrT/y) and creatine trans-
porter deficiency patients identifying reliable biomarkers
that could potentially be used to evaluate therapeutics
pre-clinically as well as clinically.
Materials and methods
Animals
We used male mice hemizygous for CrT exons 5–7
deletion (CrT/y or knockout) on a C57Bl6J
background (Baroncelli et al., 2014), and their wild-type
(WT; CrTþ/y) littermates. Animals in each experimental
group came from different litters, with a minimum of
three litters to prevent possible litter effects. Animals
were maintained at 22C under a 12-h light–dark cycle
(average illumination levels of 1.2 cd/m2) and housed in
standard cages according to current regulations about
animal welfare. Food (4RF25 GLP Certificate, Mucedola)
and water were available ad libitum. Genomic DNA was
isolated from mouse tail (Dneasy Blood and Tissue Kit,
Qiagen, USA) and genotyping was performed as previous-
ly described (Baroncelli et al., 2014). All experiments
were carried out in accordance with the European
Directive of 22 September 2010 (EU/63/2010) and were
approved by the Italian Ministry of Health (authorization
number 507/2018-PR).
EEG recordings in mice
A two-channel headmount (8201, Pinnacle Technology)
for EEG recordings was placed on the skull of mice
anaesthetized with isoflurane (1–3%). EEG electrodes
were stainless steel screws implanted epidurally over the
frontal and the occipital areas. EEG signals were
recorded using a preamplifier (8202-SL) connected to a
data acquisition system (8206, Pinnacle Technology) and
Sirenia Software 1.7.9 (Pinnacle Technology). Signals
were recorded at 400 Hz sampling frequency to evaluate
baseline (spontaneous) activity for 24 h followed by treat-
ment with intraperitoneal kainic acid at 10 mg/kg to
evoke seizure activity. Video was recorded in parallel
during the entire duration of the EEG assessments. For
the analysis of baseline EEG, signals were segmented in
30 s epochs. The vigilance state in each epoch was manu-
ally classified as active wake, passive wake or sleep,
based on the inspection of video recordings by an oper-
ator blind to the genotypes. EEG signals were converted
into power spectra by Fast Fourier Transform for at least
12 epochs in each light/dark cycle and wake/sleep condi-
tion. Consecutive epochs of the same vigilance state were
selected to be spaced at least 10 min apart between each
other. The spectra were normalized to the total power of
the signal. The power spectra were averaged over subjects
in each light/dark cycle and wake/sleep condition at fre-
quency ranges divided into five bands as follows: 0.5–4
(delta), 4–8 (theta), 8–12 (alpha), 12–30 (beta) and 30–
45 (gamma) Hz (Kadam et al., 2017). A correlation ma-
trix of EEG spectral power in CrT/y and WT animals
was obtained using Spearman correlation, with
Benjamini–Hochberg adjustment (Python, scipy library).
To quantify both baseline (spontaneous) and kainic acid-
evoked seizure episodes we used Sirenia Seizure Pro 1.8.4
(Pinnacle Technology). The baseline period of each ani-
mal was used as a cut-off threshold (mean line length
þ 8 standard deviation). Events in the 2–10 Hz fre-
quency range, with a line length higher than the defined
threshold, and lasting at least 10 s were identified as seiz-
ures. At the behavioural level, seizures were scored
according to Racine scale (Racine, 1972). Seizures of
stage 1 and 2 were classified as tonic events, seizures
of stage 3 were assigned to clonic events and seizures of
stage 4, 5 and 6 were categorized as tonic–clonic events.
Patients
Five subjects with creatine transporter deficiency aged to
the present date between 7.7 and 22.7 years were diag-
nosed at IRCCS Stella Maris Foundation at the age rang-
ing between 5.1 and 9 years (mean age ¼ 7.2 years;
standard deviation ¼ 1.8 years). All patients showing clin-
ical, neurochemical (Cr/creatinine urine levels and lack of
brain Cr at 1Hmagnetic resonance spectroscopy) and gen-
etical diagnosis of creatine transporter deficiency have
been recruited in this study and matched with 12 healthy
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subjects. The mean age of controls was 7.7 years (stand-
ard deviation ¼ 2.3 years). A breakdown of demographics
for creatine transporter deficiency patients is reported in
Table 1. Data have been anonymized using an alpha-
numeric code. Despite the occurrence of seizures with
predominant focal onset in patients 1, 2 and 5, no specif-
ic EEG pattern can be recognized in the clinical observa-
tion of interictal video-EEG. The experiment has been
subjected to approval by the Ethics Board (201/2019,
Pediatric Ethics Board of Tuscany) and has been per-
formed in accordance with the Declaration of Helsinki.
EEG recordings in patients
EEG recordings were performed as part of routine exam-
ination of patients with intellectual disability and lan-
guage deficits. Data were collected using a Micromed or
Grass EEG recording system. Gold ring electrodes were
placed following the international 10–20 convention for a
32-channel cap and signals were recorded at a sampling
rate of 500 Hz. For this analysis, we used the first EEG
recorded at the time of diagnosis; thus, patients were not
prescribed yet anticonvulsant medications. The spectral
power values in the same frequency bands described
above for mice were evaluated in humans (Kadam et al.,
2017). EEG recordings were screened and divided into
artefact-free segments (10 s duration for eyes closed con-
dition, 20 s duration for eyes open and sleep conditions).
EEG signal was then exported in European Data Format
and subjected to Fast Fourier Transform. Power spectra
were estimated by averaging at least 8 segments for each
behavioural state. The spectra were normalized to the
total power of the signal. Data analysis was performed
by an operator blind to the genotype.
Intrinsic optical signal imaging and
visually evoked potentials
Surgery was performed as previously described (Mazziotti
et al., 2017). Isoflurane was used as anaesthesia. A thin
layer of cyanoacrylate was poured over the exposed skull
to affix a custom-made metal ring (9 mm internal diam-
eter) in correspondence to the binocular visual cortex and
a drop of transparent nail polish was used to improve
the optical access. Intrinsic optical signal (IOS) imaging
recordings were performed under isoflurane (0.5–1%)
and chlorprothixene anaesthesia (1.5 mg/kg, intraperito-
neal) longitudinally in each animal at postnatal day
(PND) 40, PND110 and PND180. Images were visualized
using a custom Leica microscope (Leica Microsystems).
The animals were secured under the objective using a
ring-shaped magnet mounted on an Arduino-based imag-
ing chamber. Red light illumination (630 nm) was
obtained with 8 individually addressable light emitting
diodes (WS2812) fixed to the objective (Leica Z6 APO
coupled with a Leica PanApo 2.0X 10447170) by a cus-
tom 3D printed conical holder (Lupori et al., 2019).
Visual stimuli were generated using Matlab Psychtoolbox
and presented on a monitor placed 13 cm away from the
eyes of the mouse. Sinusoidal wave gratings were pre-
sented in the binocular portion of the visual field with
spatial frequency 0.03 cyc/deg, mean luminance 20 cd/m2
and contrast up to 90%. The stimulus consisted in the
abrupt contrast reversal of a grating with a temporal fre-
quency of 4 Hz for 1 s. Frames were acquired at 30 fps
with a resolution of 512 512 pixels. The signal was
averaged for at least 80 trials. Fluctuations of reflectance
(R) for each pixel were computed as the normalized dif-
ference from the average baseline (DR/R). A region of
interest was calculated on the mean image of contralat-
eral eye response by selecting the pixels in the lowest
30% DR/R of the range between the maximal and min-
imal intensity pixels, and mean evoked response was
quantitatively estimated as the average intensity within
the region of interest. [See Mazziotti et al. (2017) for fur-
ther details on signal analysis.] A separate group of ani-
mals were used for visually evoked potential experiments
at PND110 using Cheetah 32 (Neuralynx) recording sys-
tem (Mazziotti et al., 2017).
Behavioural tests
All behavioural tests were performed as previously
reported (Baroncelli et al., 2016).
Y maze: we used a Y-shaped maze with three symmet-
rical plastic arms at a 120-degree angle
(26 cm 10 cm 15 cm). Mice were allowed to freely ex-
plore the maze for 8 min. Video recordings (Noldus
Ethovision XT) were used for offline blind analysis. An
arm entry was defined as all four limbs within the arm.
A triad was defined as a set of three arm entries, when
each entry was to a different arm of the maze. The










(Cr/Crn; n.v. < 1.0)
Genetic testing
(Slc6a8 mutation)
1/M 5.0/ focal motor 8.4 22.7 2.35 c. 1006-1008 del AAC (de novo)
2/M 0.4/spasms 8.3 15.8 3.6 IV s1-2A >G
3/M No seizures 5.5 15.6 3.08 c.757 G>C (inherited)
4/M No seizures 9.0 8.3 2.12 p.Val246Cysfs*47
5/M 1.3/focal to bilateral 5.1 7.5 3.5 c.1376T>C, p. Leu459Pro
Crn: creatinine; M: male.
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number of arm entries and the number of triads were
recorded to calculate the alternation percentage. Morris
water maze: mice were trained for four trials per day
and for a total of 7 days in a circular water tank (diam-
eter, 120 cm; height, 40 cm), filled to a depth of 25 cm
with water (21–22C) added with atoxic white paint.
Four alternative starting positions defined the division of
the tank into four quadrants. A square clear Perspex
platform (11 cm 11 cm) was submerged 0.5 cm below
the water surface and placed at the midpoint of the tar-
get quadrant. Mice were allowed up to 60 s to locate the
escape platform, and their swimming paths were recorded
by the Noldus Ethovision system. On the last trial (probe
trial), the platform was removed and the swimming paths
were recorded over 60 s. Rotarod: mice were placed on a
drum with increasing rotation speed from 4 to 40 rpm in
10 min. The time spent on the drum was recorded by an
automated unit. Four consecutive trials with an inter-trial
interval of 5 min were performed in the same day.
Experimental design
The same animals were subjected to longitudinal IOS
recordings at PND40, PND110 and PND180. At least 4
days after the completion of each IOS recording, the ani-
mals were each subjected to serial neurobehavioural
assessments of cognitive and psychomotor functions [Y
maze, Rotarod, Morris Water Maze (PND110 and
PND180 only)]. At the end of the experimental schedule
(PND200), EEG recordings were performed. Data ana-
lysis was performed a posteriori by an operator blind to
the genotype of mice.
Machine learning-based classification
Scikit-learn, a Python-based library (http://scikit-learn.org/sta
ble/), was used to compute both principal component analysis
and train the classification model. The model is a supervised
machine learning algorithm called Random Forest that is
based on multiple decision tree learning. We used the Scikit-
learn implementation for this algorithm, called
ExtraTreesClassifier function. To determine an optimal set of
hyperparameters for the classifier we used the function
RandomizedSearchCV on the dataset with all the variables.
Then, we applied the Random Forest classifier adopting the
function cross_val_score with cv ¼ 3 to perform 3-fold cross-
validation. To calculate feature importance in classifier deci-
sion, we used the attribute feature_importance that is an in-
stance of the ExtraTreesClassifier expressing the fraction of
relative importance for each feature. Data from all ages of phe-
notyping (PND40, PND110 and PND180) were averaged
together.
Statistical analysis
For the assessments in mice, we estimated the sample size
needed for each experiment by performing a power ana-
lysis using G*Power (a¼ 0.05, b¼ 0.2). The estimate of
the expected difference between the experimental groups
was based on the knowledge of values of the studied par-
ameter obtained historically in the same laboratory in
CrT/y animals. For each parameter, we estimated the
minimal difference that would be biologically relevant
considering the impact of the possible difference on the
animals’ brain function and behaviour. Considering the
rarity of creatine transporter deficiency and the few
patients studied herein, we did not perform a specific
statistical analysis for the patient assessments. All statis-
tical analyses of the results were performed using
GraphPad Prism 8.0.1 and Python. Differences between
two groups were assessed with a two-tailed t-test.
Multiple t-test with Benjamini, Krieger and Yekutieli ad-
justment were used for the analysis of EEG spectral
power in mice. Multiple t-test were used for the analysis
of EEG spectral power in patients. Correlation analysis
was obtained using Spearman correlation, with
Benjamini–Hochberg adjustment. The significance of fac-
torial effects and differences among more than two
groups were evaluated with ANOVA/repeated measures
ANOVA followed by post hoc Holm–Sidak test. Fisher’s
exact test and v2 test were used to compare sampling dis-
tributions. Rank transformation was exploited for data
not normally distributed. The level of significance was
P <0.05.
Data availability
The datasets generated during this study are available
from the corresponding author on reasonable request.
Results
Creatine transporter deficiency
causes an alteration of cortical
oscillations in mice and humans
We performed 24 h video-EEG recordings in awake, free-
ly moving adult mice with a view to thoroughly examin-
ing basal brain activity of WT and CrT/y animals
(Fig. 1a). We found that CrT/y animals show significant-
ly altered power in a wide range of EEG frequencies,
including theta (4–8 Hz), alpha (8–12 Hz), beta (12–
30 Hz) and gamma (30–45 Hz) bands, both during active/
passive wake and sleep, regardless of the light or dark
phase (Fig. 1b and Supplementary Figs 1 and 2).
Interestingly, a correlation matrix to summarize spectral
density data in WT and CrT/y mice suggests an anomal-
ous synchronization of brain activity and, possibly, func-
tional connectivity in the brain of CrT/y animals.
Spectral densities in CrT/y mice showed a lower propor-
tion of positive correlations (blue patches; 59.8% versus
75.8%) and a higher percentage of inversely correlated
frequency bands (red patches; 59.8% versus 40.2%) com-
pared to WT animals (Supplementary Fig. 3).
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To obtain a clinical validation of results obtained in
the mouse model, we evaluated EEG data from creatine
transporter deficiency children diagnosed at the IRCCS
Stella Maris Foundation (Fig. 1c). We report a significant
difference between creatine transporter deficiency patients
and age-matched controls for frequency oscillations in the
delta, theta, alpha and gamma bands. These alterations
are particularly prominent in the signal recorded from
the central 3 electrode, but some of them are recurring at
the temporal 3 and occipital 1 recording sites as well
(Fig. 1d and Supplementary Figs 4–6).
CrT2/y mice display a spontaneous
epileptic phenotype
We found that 30% of CrT/y animals showed at least
one spontaneous seizure detectable both at behavioural
level and as epileptiform activity in EEG during baseline
Figure 1 Altered neural oscillations in CrT2/y mice and creatine transporter deficiency patients. (A) Schematic diagram of the
apparatus used for video-EEG recordings in awake, freely moving mice. EEG recordings were performed at PND200. For baseline EEG analysis,
signals were segmented in 30 s epochs. The vigilance state in each epoch was manually classified as active wake, passive wake or sleep, based on
the inspection of video recordings. EEG signals were converted into power spectra by Fast Fourier Transform for at least 12 epochs in each light/
dark cycle and wake/sleep condition. Consecutive epochs of the same vigilance state were selected to be spaced at least 10 min apart between
each other. The spectra were normalized to the total power of the signal. The power spectra were averaged over subjects in each light/dark
cycle and wake/sleep condition at frequency ranges divided into five bands as follows: 0.5–4 (delta), 4–8 (theta), 8–12 (alpha), 12–30 (beta) and
30–45 (gamma) Hz. (B) The patch colour indicates the relative difference between WT (n¼ 22) and CrT/y mice (n¼ 24) in the amplitude of
EEG power bands, measured in three different behavioural states (active wake, passive wake and sleep) both during the day and the night phase.
A single asterisk or a triple asterisk in the coloured patch indicates P< 0.05 and P< 0.001 (multiple t-test, corrected using the Benjamini, Krieger
and Yekutieli procedure), respectively. (C) Schematic diagram of electrode location in the 10–20 international system for EEG recordings. We
used this electrode configuration for EEG recordings in creatine transporter deficiency patients and age-matched controls. The mean age of
creatine transporter deficiency patients was 7.2 years (standard deviation ¼ 1.8 years); for controls the mean age was 7.7 years (standard
deviation ¼ 2.3 years). Electrodes used for the analysis were FP1 (frontopolar 1), C3 (central 3), T3 (temporal 3) and O1 (occipital 1). EEG
recordings were screened and divided into artefact-free segments (10 s duration for eyes closed condition, 20 s duration for eyes open and sleep
conditions). EEG signal was then exported in European Data Format and subjected to Fast Fourier Transform. Power spectra were estimated by
averaging at least 8 segments for each behavioural state. The spectral power values in the same frequency bands described above for mice were
evaluated in humans. The spectra were normalized to the total power of the signal. (D) The patch colour indicates the relative difference
between healthy controls (n¼ 12) and creatine transporter deficiency patients (n¼ 5) in the amplitude of EEG power bands, measured in three
different behavioural states (eyes open, eyes closed and sleep). A single asterisk or a double asterisk in the coloured patch indicates P< 0.05 and
P< 0.01 (multiple t-test), respectively. Representative EEG traces and power spectrum plots are also shown.
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recording (24 h), whereas no ictal events were detected in
WT littermates (Fig. 2a). Notably, CrT/y mice with the
spontaneous epileptic phenotype display on average one
electrographical seizure every 2 h (Fig. 2b), with a mean
duration of 20 s (Fig. 2c), that simultaneously presented
as clonic or tonic–clonic convulsions at the behavioural
level in most cases (1.4% of tonic seizures, 54.3% of
clonic seizures, 44.3% of tonic–clonic seizures;
Supplementary Videos 1 and 2). The larger portion of
spontaneous seizures occurred during passive wake (7.1%
during active wake, 62.9% during passive wake, 30.0%
during sleep). The stratification of power spectra revealed
a specific decrease in theta band in CrT/y animals dis-
playing spontaneous epilepsy (Fig. 2d–i). Moreover,
CrT/y mice presented a distinct response to kainic acid
challenge compared to WT mice. Statistical analysis
revealed a significant effect of genotype with a higher
Racine behavioural score following kainic acid adminis-
tration (Fig. 3a), lower latency to epileptiform activity
bursts (Fig. 3b) and higher frequency and mean duration
of epileptiform bursts in CrT/y with respect to WT mice
(Fig. 3c and d). In addition, the distribution of seizure se-
verity was significantly different between the two groups
with CrT/y mice presenting a high percentage of tonic–
clonic seizures (Fig. 3e).
Taken together, these data reveal that CrT/y mice ex-
hibit spontaneous seizures and increased susceptibility to
pro-convulsant treatment. Moreover, the power of theta
EEG band in CrT/y animals appears to be predictive of
spontaneous seizures phenotype.
Altered neurovascular coupling is
present in CrT2/y mutants
We examined cortical responses to visual stimulation
using intact skull IOS imaging in juvenile (PND40)
CrT/y animals. Figure 4a shows typical examples of
responses from CrT/y and age-matched WT littermates.
Data analysis revealed that IOS amplitude of the
responses driven by contralateral eye stimulation was sig-
nificantly higher in CrT/y compared to control mice and
the effect was particularly evident at higher contrasts of
visual stimuli (Fig. 4b). We longitudinally tracked visual
responses in the same animals as they aged using the
90% contrast visual stimuli. The response to the contra-
lateral eye showed a similar pattern at PND110 and
PND180 with a significantly increased amplitude in
CrT/y compared to WT mice (Fig. 4c). Moreover, the la-
tency to response peak was higher in CrT/y at PND110
and PND180 (Fig. 4d). These results show that haemo-
dynamic response is markedly altered in the cortex of
mutant animals, and that this phenotype progresses with
age. To clarify whether this is related to a corresponding
change of ongoing neuronal activity, we assessed visual
Figure 2 Spontaneous epileptic phenotype in CrT2/y animals and stratification of EEG power data according to this
phenotype. (A) Using baseline EEG recordings (24 h), we found that 30% of CrT/y mice (n¼ 24) display spontaneous seizures, while no ictal
events were detected in WTanimals (n¼ 22). On the right, a representative seizure in a CrT/y mouse is shown. Calibration bar: 100 mV, 10 s.
(B) Frequency of spontaneous seizures in CrT/y epileptic animals. (C) Average duration of spontaneous seizures in CrT/y epileptic animals.
(D–I) Violin plots with individual values (filled circles) depict normalized theta power spectrum of cortical EEG recordings from epileptic
(CrT/y seiz, n¼ 7) and non-epileptic CrT/y mice (CrT/y, n¼ 17). Decreased power of 4–8 Hz theta frequency band in epileptic CrT/y mice
during the passive wakefulness and sleep in the light phase, and during the active and passive wakefulness in the dark phase. Multiple t-tests with
adjusted P-value: *P< 0.05, **P< 0.01. Error bars, standard deviation.
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responses in a separate group of adult (PND110) CrT/y
mice using intracortical visually evoked potential record-
ings. Data quantification revealed comparable visually
evoked potential amplitude and latency in CrT/y and
WT animals (Fig. 4e and f).
A Random Forest classifier quantify
robustness of creatine transporter
deficiency biomarkers
Longitudinal IOS imaging was conducted along with ser-
ial neurobehavioural assessments of cognitive and psycho-
motor functions (Y maze, Rotarod, Morris Water Maze).
At the end of the experimental schedule, EEG recordings
were performed in the same animals at PND180. Results
of behavioural testing confirmed what was previously
reported by our group (Baroncelli et al., 2016;
Supplementary Figs 7–9). To evaluate the reliability of
the behavioural phenotype, imaging and electrophysio-
logical recordings as biomarkers of creatine transporter
deficiency disorder, we computed accuracy using a
Random Forest binary classifier, a supervised machine
learning algorithm for data classification. When trained
with the entire dataset, the algorithm showed a
remarkable capability to discriminate between CrT/y and
WT animals (Full; accuracy ¼ 95.67%; Fig. 5b). As a
control, we also repeated the procedure after bootstrap-
ping the dataset (Bootstrap; accuracy ¼ 54.86%). We
then assessed the discriminative performance of smaller
subsets of data dividing the entire dataset in behavioural
(Behaviour), imaging (IOS) and electrophysiological
(EEG) variables. We found that behavioural (accuracy ¼
95.45%), IOS (accuracy ¼ 90.84%) and EEG (accuracy
¼ 88.1%) models showed significantly better performance
than the bootstrap condition, establishing the robustness
and reliability of these phenotypes in our mouse model
(Fig. 5a and b). Importantly, the analysis of feature im-
portance highlighted that the most informative variables
are Y maze, IOS amplitude and alpha band (night, active
wake) in EEG recordings (Fig. 5c).
Discussion
Quantitative biomarkers measuring cortical function are a
fundamental tool for the development of therapeutics,
and different techniques have been recently and success-
fully introduced in clinical and research settings for
neurodevelopmental disorders (Bosl et al., 2011;
Figure 3 Kainic acid challenge in the brain of CrT2/y mice. (A) Kainic acid injection (10 mg/kg) induced overt seizures in 100% of CrT/y
mice (n¼ 24), whereas only 14/22 WTanimals displayed epileptic bursts at electrographical level over 1 h of observation. (B) Effect of kainic acid
treatment at the behavioural level. Circles represent the maximum seizure rating score of individual WTand CrT/y mice over a period of 1 h
after kainic acid administration. Black lines represent mean with 95% confidence interval. CrT/y mice displayed a higher Racine score (t-test,
P< 0.001). (C–F) Severity of kainic acid-induced seizures in WTand CrT/y mice at electrophysiological level. EEG analysis was performed on
the same animals used for behavioural scoring. CrT/y mice showed a lower latency to the first seizure (C, t-test, P< 0.001), and increased
frequency (D, t-test, P< 0.001) and duration (E, t-test, P< 0.05) of seizure events with respect to age-matched littermates. For WTanimals not
presenting seizures during the 1 h of monitoring, we extended the observation until the occurrence of the first electrographical burst to provide
a latency value. Circles represent single data values; black lines indicate mean with 95% confidence interval. Relative percentage of tonic, clonic
and tonic–clonic seizures WTand CrT/y mice (F) indicates that seizure severity is more pronounced in CrT/y animals (v2 test; P< 0.001).
*P< 0.05, ***P< 0.001.
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Durand et al., 2012; Jeste et al., 2015; LeBlanc et al.,
2015; Boggio et al., 2016; Mazziotti et al., 2017;
Sinclair et al., 2017; Bowman and Varcin, 2018;
Lupori et al., 2019). Following this approach, we report
novel functional biomarkers for creatine transporter defi-
ciency, capable of classifying animal genotypes at single
subject level with high accuracy and sensitivity (>85%)
and to measure disease progression. These tools may be
of high translational value for future preclinical studies of
creatine transporter deficiency, and also more broadly for
neurodevelopmental disorders presenting with cognitive
dysfunction, autistic-like features and brain
hyperexcitability.
The clinical relevance of the spectral changes of EEG
signal apparent in CrT/y mice was demonstrated by our
findings showing a comparable dysfunction of neural
oscillations in creatine transporter deficiency patients.
More specifically, theta and alpha power was decreased
in the cerebral cortex of CrT/y mice compared to WT
animals, whereas beta and gamma power was increased,
highlighting a transition from physiological to pathologic-
al network activity similar to that observed in other neu-
rodevelopmental disorders and patients in the autistic
spectrum (Jeste et al., 2015; Sinclair et al., 2017).
Importantly, theta and alpha bands were altered in the
same direction in mice and patients, identifying a possible
‘network biomarker’ of creatine transporter deficiency
disorder. Moreover, we demonstrated that CrT/y mice
display an epileptic phenotype, with spontaneous seizure
occurrence and increased susceptibility to kainic acid, as
assessed through behavioural observation and video-EEG
recordings in awake animals. Since epilepsy is common in
creatine transporter deficiency (van de Kamp et al., 2014)
and seizures are one of the symptoms with the greatest
impact on quality of life of patients and caregivers, these
findings fill a gap in the current literature and expand
Figure 4 Altered haemodynamic response in CrT2/y animals. (A) Typical IOS response to visual stimulation in the binocular visual field
for a WT (CrTþ/y) and a CrT/y animal. The Look Up Table is shown on the right. Scale bar: 1.8 mm. (B) Contrast-response function for
contralateral eye stimulation in male WT (n¼ 6) and CrT/y (n¼ 9) mice at PND40. IOS amplitude was increased in CrT/y animals in particular
at high contrast of visual stimuli (two-way ANOVA, effect of genotype P< 0.05, genotype contrast interaction P< 0.05, post hoc Holm–Sidak
method, P< 0.01 at 90% of contrast). (C) Response for contralateral eye stimulation in male WTand CrT/y mice at three different time points
(PND40, PND110 and PND180; n¼ 15 for each group at PND40 and PND110, n¼ 19 at PND180). IOS amplitude was significantly increased in
CrT/y animals (two-way ANOVA, effect of genotype P< 0.001, post hoc Holm–Sidak method, P< 0.001 at all ages tested). (D) The latency of
IOS responses was longer in CrT/y mice at PND110 and PND180 (two-way ANOVA, effect of genotype P< 0.001, post hoc Holm–Sidak
method, P< 0.001). (E, F) No differences in visually evoked potential amplitude (E) and latency (F) were detected between WT (n¼ 10) and
CrT/y animals (n¼ 7; t-test, P¼ 0.767 and P¼ 0.087, respectively) at PND110. For all panels, circles represent single data values; black lines
indicate mean with 95% confidence interval. Representative visually evoked potential traces for a WT (continuous black line) and a CrT/y
(dashed blue line) mouse are also shown on the right. **P< 0.01, ***P< 0.001. Error bars, SEM.
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the translational validity of our creatine transporter defi-
ciency murine model. The stratification of animals based
on the manifestation of spontaneous seizures revealed
that epileptic mice exhibit a specific decrease in theta
power band with respect to non-epileptic animals. This
result is in agreement with previous literature showing
that changes in theta band power can be predictive of
epilepsy (Bettus et al., 2008; Milikovsky et al., 2017).
Since the timing of rhythmic activity in cortical net-
works strongly affects the coordination of neuronal
responses throughout the cortex, the EEG alterations
found in creatine transporter deficiency mice and patients
establish a robust link between alterations in brain oscil-
latory activity and the pervasive cognitive and behaviour-
al impairment of this condition, suggesting that a
derangement in local and long-range cortical connectivity
and plasticity could be a good candidate to explain at
the network level the pathological endophenotype of
creatine transporter deficiency (e.g. Jensen and Tesche,
2002; Klimesch et al., 2007; Summerfield and Egner,
2009; Uhlhaas et al., 2009; Jensen and Mazaheri, 2010;
Güntekin et al., 2013; Nicolás et al., 2019). The increase
in beta and gamma power could seem at odds with the
observed cognitive deficits and natural history of creatine
transporter deficiency, but excessive beta/gamma activity
was previously associated with increased brain excitability
and seizures (Willoughby et al., 2003; Maheshwari et al.,
2016). In summary, the observed EEG abnormalities may
be related to different symptoms in creatine transporter
deficiency. Future studies analysing the effects of specific
pharmacological approaches (such as anticonvulsant
drugs) on EEG components in creatine transporter defi-
ciency patients are needed to further test this notion.
We also found a highly specific increase in cortical IOS
responses in CrT/y mice. Since IOS imaging measures
blood oxygenation level-dependent signals, these data
Figure 5 Random Forest analysis of the dataset. (A) Scatter plot of all the experimental subjects analysed with the full dataset (Full),
behavioural (Behaviour), IOS imaging (IOS) and EEG variables plotted in the space of the first two principal components of principal component
analysis. (B) Comparison of accuracy for different Random Forest classifiers trained and tested, respectively, with the entire dataset, behavioural,
IOS, EEG variables and randomly permuted dataset (Bootstrap). A Kruskal–Wallis analysis followed by Dunn’s multiple comparisons revealed
that the behavioural variable has an accuracy comparable to the full dataset, whereas the accuracy of IOS and EEG variables is slightly lower. All
classifiers displayed a higher accuracy than Bootstrap (P< 0.001 for all comparisons). Error bars, standard deviation. (C) Histogram depicts the
relative importance of top 14 features in the Random Forest model. daw: day active wake; dpw: day passive wake; ds: day sleep; ios-amp:
amplitude of IOS; ios-lat: latency of IOS; KAfreq: frequency of seizures after kainic acid challenge; mwm-train: training distance of Morris water
maze; naw: night active wake; npw: night passive wake; ns: night sleep; rot: rotarod. *P< 0.05, **P< 0.01, ***P< 0.001, ns, not significant.
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suggest that the assessment of brain metabolic consump-
tion might represent a further non-invasive and sensitive
biomarker for the analysis of brain function in creatine
transporter deficiency. In light of the ubiquitous expres-
sion of Slc6a8 gene in the brain at the cellular and re-
gional level (Mak et al., 2009), the normal visually
evoked potential amplitude recorded in the visual cortex
of CrT/y mice suggests that glial and vascular cells
might be the cellular basis of altered IOS. Accordingly,
the forced metabolic phenotype and the resultant increase
in cellular oxidative stress observed in the brain of CrT/
y animals (Giusti et al., 2019) could dynamically upregu-
late the cerebral blood flow stimulating vasodilation
(Watts et al., 2018). Abnormal neurovascular coupling
could significantly affect functional magnetic resonance
imaging responses in creatine transporter deficiency
patients and represent another creatine transporter defi-
ciency biomarker of relatively easy assessment in children
using functional near-infrared spectroscopy (Lloyd-Fox
et al., 2010; Vanderwert and Nelson, 2014).
Using a Random Forest machine learning algorithm for
data classification, we showed that behavioural, imaging
and EEG assessment can be used to automatically classify
subjects. Since ease of testing is a key factor in complex
multidose assessments, we also showed that smaller sub-
sets of variables could reach a similar discriminative
performance.
Overall, our findings identify novel, translational and
non-invasive biomarkers for the investigation of brain
function in creatine transporter deficiency. Despite the
availability of reliable tools for creatine transporter defi-
ciency diagnosis, including biochemical, magnetic reson-
ance spectroscopy and genetic analyses, the biomarkers
discovered in this work will have a fundamental impact
in the research and clinical setting at multiple levels: (i)
their evaluation will allow clinicians to optimize the fol-
low-up of patients, recognizing possible alterations of
brain circuits during the progression of creatine transport-
er deficiency disorder; (ii) the study of EEG pattern could
be predictive of the epileptic phenotype; (iii) the combin-
ation of behavioural, IOS and EEG testing provides a
very reliable protocol to longitudinally monitor the effi-
cacy of potential therapeutic strategies in preclinical, and
possibly clinical, studies. It is worth noting that much ef-
fort has been invested so far in the research of therapeut-
ic strategies aimed at replenishing brain Cr levels, but
efficacy studies of pharmacological approaches targeting
specific pathogenetic mechanisms of creatine transporter
deficiency disorder need to rely on direct measurements
of brain function.
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